Validation of comparative genomic hybridization

• US 20070238108A1
• Filed: 04/07/2006
• Published: 10/11/2007
• Est. Priority Date: 04/07/2006
• Status: Abandoned Application

• Current Assignee: Agilent Technologies, Inc.
• Original Assignee: Agilent Technologies, Inc.
• Inventors: Barrett, Michael, Caren, Michael
• Application Number:
  US11/400,559
• Publication Number:
  US 20070238108A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6876 Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

Abstract

The present invention generally relates to techniques involving comparative genomic hybridization (CGH) and related techniques, including the validation of assay results. In one aspect, a region of interest of a genome or other target nucleic acid, identified using CGH or similar techniques, may be validated using a probe based on the CGH results. The oligonucleotides, in some embodiments, may bind the genome in some fashion (e.g., to the region of interest, and/or to other predetermined regions), and thus can be used for validation of CGH or other results.

Claims

1. A method for validating a CGH assay, the method comprising acts of:

selecting a sequence within a target DNA based on the results of a CGH assay;

exposing the target DNA to an oligonucleotide probe comprising a sequence able to hybridize to a portion of the target DNA; and

determining association of the oligonucleotide probe with the target DNA, thereby validating the CGH assay.

2. The method of claim 1, wherein the oligonucleotide probe has a length of between 10 nucleotides and 200 nucleotides.

3. The method of claim 1, wherein the oligonucleotide probe has a length of between 100 nucleotides and 200 nucleotides.

4. The method of claim 1, wherein the oligonucleotide probe is substantially free of repetitive sequences.

5. The method of claim 1, wherein the oligonucleotide probe comprises a detection entity.

6. The method of claim 1, wherein the portion of the target DNA that the sequence of the oligonucleotide probe is able to hybridize to has a non-normal copy number.

7. The method of claim 1, wherein the CGH assay is aCGH.

8. The method of claim 1, comprising determining the association of the oligonucleotide probe with the target DNA using fluorescence.

9. The method of claim 1, comprising exposing the target DNA to a plurality of oligonucleotide probes, at least some of which are non-identical, at least some of the oligonucleotide probes each comprise a sequence able to hybridize to a portion of the target DNA.

10. The method of claim 9, wherein at least some of the non-identical oligonucleotide probes are able to bind to non-identical portions of the target DNA.

11. The method of claim 1, further comprising amplifying the oligonucleotide probe.

12. The method of claim 1, further comprising identifying said target DNA.

13. A method for validating a genomic region of interest, the method comprising acts of:

selecting a genomic region of interest;

exposing the genomic region of interest to an oligonucleotide probe comprising a sequence able to hybridize to a portion of the genomic region of interest; and

determining association of the oligonucleotide probe with the genomic region of interest.

14. The method of claim 13, comprising selecting the genomic region of interest using a CGH assay.

15. A composition, comprising:

a plurality of oligonucleotide probes, including a first oligonucleotide probe and a second oligonucleotide probe different from the first oligonucleotide probe, each of the first and second oligonucleotide probes comprising respective first and second sequences able to specifically hybridize to respective first and second portions of a genome, wherein the first portion and the second portion are in contact or are separated along the genome by a distance of no more than 1,000 bases.

16. The composition of claim 15, wherein the first oligonucleotide probe and the second oligonucleotide probe are each attached to a substrate.

17. A method, comprising:

synthesizing a first oligonucleotide probe and a second oligonucleotide probe different from the first oligonucleotide probe, each of the first and second oligonucleotide probes comprising respective first and second sequences able to specifically hybridize to respective first and second portions of a genome, wherein the first portion and the second portion are in contact or are separated along the genome by a distance of no more than 1,000 bases.

18. A kit, comprising:

a first oligonucleotide probe; and

a second oligonucleotide probe different from the first oligonucleotide probe,

wherein each of the first and second oligonucleotide probes comprises respective first and second sequences able to specifically hybridize to respective first and second portions of a genome, wherein the first portion and the second portion are in contact or are separated along the genome by a distance of no more than 1,000 bases.

19. A method, comprising:

synthesizing a plurality of oligonucleotides on a substrate, including a first oligonucleotide probe and a second oligonucleotides different from the first oligonucleotide probe, each of the first and second oligonucleotides comprising respective first and second sequences able to specifically hybridize to respective first and second portions of a genome, wherein the first portion and the second portion are in contact or are separated along the genome by a distance of no more than 1,000 bases; and

cleaving at least some of the oligonucleotides from the substrate.

20. An article, comprising:

an array comprising a plurality of oligonucleotide probes, including a first oligonucleotide probe and a second oligonucleotide probe different from the first oligonucleotide probe, each of the first and second oligonucleotide probes comprising respective first and second sequences able to specifically hybridize to respective first and second portions of a genome, wherein the first portion and the second portion are in contact or are separated along the genome by a distance of no more than 1,000 bases.